Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FBRX NASDAQ:MCRB NASDAQ:RADX NASDAQ:SLS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBRXForte Biosciences$15.49+15.3%$11.79$4.11▼$28.68$167.10M3.03104,833 shs65,200 shsMCRBSeres Therapeutics$20.59-2.1%$17.40$6.53▼$24.67$184.20M0.19268,113 shs264,845 shsRADXRadiopharm Theranostics$6.20+2.3%$5.63$3.50▼$50.82$47.77MN/A28,753 shs5,746 shsSLSSELLAS Life Sciences Group$1.87+9.4%$1.73$0.77▼$2.27$180.06M2.622.31 million shs3.41 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBRXForte Biosciences+15.25%+11.92%+39.93%+12.17%+203.43%MCRBSeres Therapeutics-2.14%+8.77%+11.30%+81.33%+14.10%RADXRadiopharm Theranostics+2.31%+7.83%+12.73%+55.78%+619,999,900.00%SLSSELLAS Life Sciences Group+9.36%+14.72%+5.06%-14.02%+50.81%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFBRXForte Biosciences$15.49+15.3%$11.79$4.11▼$28.68$167.10M3.03104,833 shs65,200 shsMCRBSeres Therapeutics$20.59-2.1%$17.40$6.53▼$24.67$184.20M0.19268,113 shs264,845 shsRADXRadiopharm Theranostics$6.20+2.3%$5.63$3.50▼$50.82$47.77MN/A28,753 shs5,746 shsSLSSELLAS Life Sciences Group$1.87+9.4%$1.73$0.77▼$2.27$180.06M2.622.31 million shs3.41 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFBRXForte Biosciences+15.25%+11.92%+39.93%+12.17%+203.43%MCRBSeres Therapeutics-2.14%+8.77%+11.30%+81.33%+14.10%RADXRadiopharm Theranostics+2.31%+7.83%+12.73%+55.78%+619,999,900.00%SLSSELLAS Life Sciences Group+9.36%+14.72%+5.06%-14.02%+50.81%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFBRXForte Biosciences 2.50Moderate Buy$68.00338.99% UpsideMCRBSeres Therapeutics 1.60Reduce$14.33-30.39% DownsideRADXRadiopharm Theranostics 3.00Buy$15.00141.94% UpsideSLSSELLAS Life Sciences Group 2.00Hold$7.00274.33% UpsideCurrent Analyst Ratings BreakdownLatest RADX, FBRX, MCRB, and SLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/27/2025FBRXForte BiosciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MCRBSeres TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025RADXRadiopharm TheranosticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SLSSELLAS Life Sciences GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/24/2025MCRBSeres TherapeuticsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $22.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.008/18/2025FBRXForte BiosciencesGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$75.008/15/2025FBRXForte BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$61.007/21/2025RADXRadiopharm TheranosticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$18.007/16/2025SLSSELLAS Life Sciences GroupMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$4.00 ➝ $7.00(Data available from 10/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFBRXForte BiosciencesN/AN/AN/AN/A$8.21 per shareN/AMCRBSeres Therapeutics$126.32M1.43N/AN/A$1.61 per share12.79RADXRadiopharm Theranostics$2.35M20.79N/AN/AN/A∞SLSSELLAS Life Sciences Group$1M196.91N/AN/A$0.13 per share14.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFBRXForte Biosciences-$35.48M-$16.29N/AN/AN/AN/A-85.38%-72.34%11/13/2025 (Estimated)MCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-350.16%-67.69%11/12/2025 (Estimated)RADXRadiopharm TheranosticsN/AN/A0.00∞N/AN/AN/AN/AN/ASLSSELLAS Life Sciences Group-$30.88M-$0.32N/AN/AN/AN/A-132.51%-92.79%11/12/2025 (Estimated)Latest RADX, FBRX, MCRB, and SLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025FBRXForte Biosciences-$1.21-$0.96+$0.25-$0.96N/AN/A8/12/2025Q2 2025SLSSELLAS Life Sciences Group-$0.0767-$0.07+$0.0067-$0.07N/AN/A8/6/2025Q2 2025MCRBSeres Therapeutics-$2.72-$2.27+$0.45-$2.27$11.75 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFBRXForte BiosciencesN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ARADXRadiopharm TheranosticsN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFBRXForte BiosciencesN/A11.7411.74MCRBSeres TherapeuticsN/A1.571.57RADXRadiopharm TheranosticsN/AN/AN/ASLSSELLAS Life Sciences GroupN/A4.914.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFBRXForte Biosciences77.63%MCRBSeres Therapeutics59.34%RADXRadiopharm TheranosticsN/ASLSSELLAS Life Sciences Group17.38%Insider OwnershipCompanyInsider OwnershipFBRXForte Biosciences5.90%MCRBSeres Therapeutics4.70%RADXRadiopharm TheranosticsN/ASLSSELLAS Life Sciences Group1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFBRXForte Biosciences512.43 million11.70 millionOptionableMCRBSeres Therapeutics3308.75 million8.34 millionOptionableRADXRadiopharm TheranosticsN/A7.88 millionN/AN/ASLSSELLAS Life Sciences Group10105.30 million103.82 millionNot OptionableRADX, FBRX, MCRB, and SLS HeadlinesRecent News About These CompaniesSELLAS Extends Times Square Sublease AgreementOctober 3 at 4:50 PM | tipranks.comSELLAS Life Sciences Group to Host Virtual R&D Day on October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL ...September 30, 2025 | markets.businessinsider.comSELLAS Life Sciences Group (NASDAQ:SLS) Shares Down 9.2% - Should You Sell?September 17, 2025 | marketbeat.comSELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current ...September 13, 2025 | bakersfield.comBSellas Life Sciences Stock In Spotlight After Institutional Investor Exercises Existing WarrantsSeptember 12, 2025 | msn.comSELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross ProceedsSeptember 11, 2025 | markets.businessinsider.comSELLAS Life Sciences Group, Inc. Announces Immediate Exercise of Warrants, Raising Approximately $23.6 MillionSeptember 11, 2025 | quiverquant.comQSellas Life Sciences: SLS009's Phase 2 Sets Up A Promising 2026August 19, 2025 | seekingalpha.comSellas Life Sciences Reports Q2 2025 Financial ResultsAugust 13, 2025 | msn.comSellas Life Sciences reports Q2 EPS (7c), consensus (8c)August 12, 2025 | msn.comSELLAS Life Sciences Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 12, 2025 | finance.yahoo.comSELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without ...August 9, 2025 | finance.yahoo.comSELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 REGAL Trial of GPS in AML Without ModificationAugust 7, 2025 | globenewswire.comSELLAS Life Sciences Group (SLS) Upgraded to Buy: What Does It Mean for the Stock? (Revised)July 31, 2025 | zacks.comSellas Flat on Trial SuccessJuly 16, 2025 | baystreet.caSELLAS gains as mid-stage trial for leukemia drug succeedsJuly 16, 2025 | msn.comSELLAS Life Sciences Group Welcomes Dr. Linghua Wang to Scientific Advisory Board - NasdaqJuly 9, 2025 | nasdaq.comSellas Life Sciences appoints Linghua Wang to Scientific Advisory BoardJuly 7, 2025 | msn.comSELLAS Life Sciences Appoints Linghua Wang, MD, PhD, to Scientific Advisory BoardJuly 7, 2025 | globenewswire.comSELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® IndexesJune 24, 2025 | finance.yahoo.comGalena Biopharma (SLS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo FinanceJune 24, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRADX, FBRX, MCRB, and SLS Company DescriptionsForte Biosciences NASDAQ:FBRX$15.49 +2.05 (+15.25%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$15.02 -0.47 (-3.00%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc. is headquartered in Dallas, Texas.Seres Therapeutics NASDAQ:MCRB$20.59 -0.45 (-2.14%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$20.30 -0.29 (-1.41%) As of 10/3/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Radiopharm Theranostics NASDAQ:RADX$6.20 +0.14 (+2.31%) As of 10/3/2025 03:55 PM EasternRadiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.SELLAS Life Sciences Group NASDAQ:SLS$1.87 +0.16 (+9.36%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$1.88 +0.00 (+0.27%) As of 10/3/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet: After Its Best Quarter in Decades, Is It Time to Buy? After Trump Deal, Can Meta Stock Withstand TikTok’s Onslaught? How Berkshire's OxyChem Buy Cements Its Long-Term Strength NVIDIA Breaks Out to New Highs: What Comes Next? Down 22% From Highs, ServiceNow Could Be Too Cheap to Ignore Microsoft Stock Hits Stride in 2025—How Much More Can It Run? Datavault AI: The New AI Contender Backed by Big Funding Why GlobalFoundries Just Became a Geopolitical Power Play Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
